The association of centromere amplification and response to trastuzumab in HER2+metastatic breast cancer

被引：0
|
作者：
Andrieu, Charlotte
Al-Sultan, Dalal
Ivers, Laura
Pina, Jose Javier Berenguer
Skrobo, Darko
Ballot, Josephine
Eustace, Alex J.
Gullo, Giuseppe
Crown, John
机构：
[1] Dublin City Univ, Sch Biotechnol, Natl Inst Cellular Biotechnol, Dublin, Ireland
[2] St Vincents Univ Hosp, Dept Med Oncol, Dublin, Ireland
[3] CCRT Caroline Fdn, Dublin, Ireland
[4] Galway Univ Hosp, Dept Histopathol, Galway, Ireland
[5] St Vincents Univ Hosp, Dept Med Oncol, Dublin, Ireland
[6] St Vincents Univ Hosp, Dept Pathol, Dublin, Ireland
[7] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1016
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Retrospective analysis of long-term survivors with HER2+metastatic breast cancer (MBC) treated with trastuzumab in a community setting
    Jones, S.
    Tseng, W-Y
    Saravanan, S.
    Santos, E.
    Dhanda, R.
    Rembert, D. S.
    Yap, M. A.
    Lalla, D.
    Brammer, M.
    CANCER RESEARCH, 2013, 73
  • [42] HER2, EGFR, PIK3CA mutations in HER2+metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T): Incidence and correlation with response
    Gori, S.
    Ludovini, V.
    Colozza, M.
    Pistola, L.
    Tofanetti, F. R.
    Flacco, A.
    Foglietta, J.
    Minenza, E.
    Stocchi, L.
    De Angelis, V.
    Crino, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB plus DOCETAXEL VERSUS DOCETAXEL ALONE IN THE TREATMENT OF HER2+METASTATIC BREAST CANCER
    Athanasakis, K.
    Golna, C.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2011, 14 (07) : A449 - A449
  • [44] Evolving perspectives on the treatment of HR+/HER2+metastatic breast cancer
    Pegram, Mark
    Pietras, Richard
    Dang, Chau T.
    Murthy, Rashmi
    Bachelot, Thomas
    Janni, Wolfgang
    Sharma, Priyanka
    Hamilton, Erika
    Saura, Cristina
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [45] Efficacy, safety and tolerability of dual monoclonal antibody therapy with pertuzumab plus trastuzumab in HER2+metastatic breast cancer patients previously treated with trastuzumab
    Baselga, J.
    Imadalou, K.
    Paton, V
    Gray, D.
    Swain, S.
    CANCER RESEARCH, 2009, 69 (02) : 243S - 244S
  • [46] An Evaluation of the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2+Metastatic Breast Cancer
    Esteva, F. J.
    Franco, S. X.
    Hagan, M. K.
    Somer, R. A.
    Dombroski, C. S.
    Florance, A. M.
    Turner, S. J.
    Stein, S.
    Perez, A.
    CANCER RESEARCH, 2009, 69 (24) : 793S - 793S
  • [47] Updated efficacy and safety assessment of first-line therapy with lapatinib, trastuzumab, and paclitaxel in HER2+metastatic breast cancer
    Esteva, F. J.
    Franco, S.
    Hagan, M. K.
    Brewster, A.
    Williams, W.
    Florance, A. M.
    Koch, K.
    Turner, S. J.
    Ridderheim, M.
    Perez, A. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] The role of tyrosine kinase inhibitors in the treatment of HER2+metastatic breast cancer
    Le Du, Fanny
    Dieras, Veronqiue
    Curigliano, Giuseppe
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 175 - 189
  • [49] Real-world treatment in patients with HER2+metastatic breast cancer
    Colomer, R.
    Hall, P.
    Szkultecka-Debek, M.
    Bondi, R. C.
    Flinois, A.
    Auziere, S.
    Le Cleac'h, J. Y.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) : 197 - 205
  • [50] registHER: An observational cohort study of patients with HER2+metastatic breast cancer
    Yood, Marianne Ulcickas
    Kaufman, Peter A.
    Mayer, Musa
    Rugo, Hope
    Brufsky, Adam
    Tan-Chiu, Elizabeth
    Yardley, Denise
    Paik, Soonmyung
    Wang, Lisa
    Birkner, Merrill
    Brammer, Melissa
    Tripathy, Debu
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S40 - S40
12345